ArticleInternational journal of radiation oncology, biology, physics2023
Salvage Radiation Therapy After Radical Prostatectomy: Analysis of Toxicity by Dose-Fractionation in the RADICALS-RT Trial.
Article in International journal of radiation oncology, biology, physics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07483658 (Non-Inferiority Study Comparing Hypofractionated Post-Operative Salvage Radiotherapy Regimens), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Non-Inferiority Study Comparing Hypofractionated Post-Operative Salvage Radiotherapy Regimens: 45/62.5 Gy in 25 Fractions vs. 43/52.5 Gy in 20 Fractions for Grade 2+ GU or GI Toxicity (HYP-OP-RT)
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Fecal incontinence after prostate cancer irradiation: a systematic literature review.Prostate cancer and prostatic diseases · 2026Pooled it
- Biochemical Recurrence Irradiation or Observation (BRIO) in patients with prostate cancer: protocol for a randomised control trial.BJU international · 2026Trial
- A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single Institution.European urology oncology · 2026Trial
- Early adverse events and patient-reported outcomes after salvage radiotherapy following prostatectomy according to fractionation schedule: Interim analysis of the phase III URONCOR 06-24 trial.Clinical and translational radiation oncology · 2026Article
- Article
- Daily adaptive radiotherapy in postoperative hypofractionated salvage radiothERapy for prostate cancer patients (DART-PHASER): Early clinical and dosimetric results.Clinical and translational radiation oncology · 2026Article
- Multicenter ProKnow-based plan evaluation of postprostatectomy salvage radiotherapy patients using SPPORT and RADICALS-HD trial-defined dose constraints.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- Long-term Outcomes of Toxicities and Disease Control Following Postoperative Moderately Hypofractionated Radiotherapy in High-Risk Prostate Cancer: Results of a Prospective Study.Clinical and translational radiation oncology · 2026Article
- Temporal Patterns and Resolution of Toxicities Following Hypofractionated Salvage Radiotherapy for Biochemical Recurrence of Prostate Cancer After Prostatectomy.The Prostate · 2026Article
- Acute toxicity and quality of life in postoperative prostate cancer patients treated with ultra-hypofractionated pelvic radiation therapy.Radiation oncology journal · 2026Article
- Salvage stereotactic body radiotherapy for post-prostatectomy recurrence: are we almost there?Journal of radiation research · 2026Review
- Outcome and Toxicity of Moderately Hypofractionated Post-Prostatectomy Radiotherapy: A Retrospective Study.Medical sciences (Basel, Switzerland) · 2025Article
- The Surgical Imprint: How Operative Trauma May Shape Radiation Tolerance After Prostatectomy.Cancers · 2025Article
- Article
- Exploring the dosimetric advantages of a novel multi-modality radiotherapy platform in prostate cancer.Physical and engineering sciences in medicine · 2025Article
- More micrometastases, more recurrence? The role of qPCR of PSA mRNA in lymph nodes during prostatectomy.World journal of urology · 2025Article
- Radiation Therapy for Local or Biochemical Recurrence Following Radical Prostatectomy in Patients with Prostate Cancer.Research and reports in urology · 2025Article
- Review
- Article
- Recurrent prostate adenocarcinoma after radical prostatectomy: Principles of multidisciplinary management across a spectrum of disease.CA: a cancer journal for cliniciansArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 13 institutions in 3 countries.
Funding
Abstract
purposeEmerging data indicate comparable disease control and toxicity of normal postoperative fractionation and moderate hypofractionation radiation therapy (RT) in prostate cancer. In RADICALS-RT, patients were planned for treatment with either 66 Gy in 33 fractions (f) over 6.5 weeks or 52.5 Gy in 20f over 4 weeks. This non-randomized, exploratory analysis explored the toxicity of these 2 schedules in patients who had adjuvant RT. METHODS AND MATERIALS: Information on RT dose was collected in all patients. The Radiation Therapy Oncology Group toxicity score was recorded every 4 months for 2 years, every 6 months until 5 years, then annually until 15 years. Patient-reported data were collected at baseline and at 1, 5, and 10 years using standard measures, including the Vaizey fecal incontinence score (bowel) and the International Continence Society Male Short-Form questionnaire (urinary incontinence). The highest event grade was recorded within the first 2 years and beyond 2 years and compared between treatment groups using the χ² test.
resultsOf 634 patients, 217 (34%) were planned for 52.5 Gy/20f and 417 (66%) for 66 Gy/33f. In the first 2 years, grade 1 to 2 cystitis was reported more frequently among the 66 Gy/33f group (52.5 Gy/20f: 20% vs 66 Gy/33f: 30%; P = .04). After 2 years, grade 1 to 2 cystitis was reported in 16% in the 66-Gy group and 9% in the 52.5-Gy group (P = .08). Other toxic effects were similar in the 2 groups, and very few patients had any grade 3 to 4 toxic effects. Patients reported slightly higher urinary and fecal incontinence scores at 1 year than at baseline, but no clinically meaningful differences were reported between the 52.5 Gy/20f and 66 Gy/33f groups. Patient-reported health was similar at baseline and at 1 year and similar between the 52.5 Gy/20f and 66 Gy/33f groups.
conclusionsSevere toxic effects were rare after prostate bed radiation therapy with either 52.5 Gy/20f or 66 Gy/33f. Only modest differences were recorded in toxic effects or in patient-reported outcomes between these 2 schedules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.